CASE REPORT

Hepatic predominant presentation of Kawasaki disease in adolescence case report and review of literature

Krishan Pratap1,2, Logan S. Gardner1,2*, David Gillis1, Martin Newman3, Dana Wainwright1 and Roger Prentice1

Abstract

Background: Kawasaki Disease (KD) is the most common paediatric vasculitis affecting small to medium arteries. Although the average age of diagnosis is 3.4 years with a well-defined clinical presentation, older patients with KD including adolescent and adult patients demonstrate a less classical presentation with prominent findings including hepatitis, cervical lymphadenopathy, and arthralgia. We describe a case of an adolescent presentation of Kawasaki Disease presenting with a predominantly cholestatic hepatic picture.

Case presentation: We describe a case of KD in a 16-year-old Caucasian female with predominately hepatic disease that showed resistance to intravenous immunoglobulin (IVIG). The formal diagnosis of KD was made on her 8th day of symptoms. She displayed classical symptoms commencing with fever, followed by peripheral desquamation, strawberry tongue, cervical lymphadenopathy. She became clinically jaundiced with evidence of hepatic artery narrowing on ultrasound that resolved with treatment. Her disease was biphasic and required further IVIG for non-hepatic symptoms. She did not develop coronary aneurysms.

Conclusion: Significant hepatic dysfunction with clinical jaundice is rare in KD without associated gall bladder hydrops and tends to occur in older patients. We describe such a case and review the five described cases in the literature. Diagnostic delay is more common in adolescent patients and given that the prognosis of KD is closely correlated to diagnostic timing and provision of care, it is important to consider Kawasaki Disease in older demographics especially with undiagnosed hepatic disease.

Keywords: Kawasaki, Hepatitis, Liver, Adolescent, Case report

Background

Kawasaki Disease (KD) is the most common paediatric vasculitis affecting small to medium arteries [1, 2]. Previously referred to as mucocutaneous lymph node syndrome, the majority of morbidity and mortality in KD stems from cardiac involvement with the development of coronary artery aneurysms and arrhythmias [2].

The presentation is typically heralded by a prodromal phase with non-specific viral-like respiratory and gastrointestinal symptoms [1, 2]. Classic findings that form the diagnosis of complete KD as defined by Tomisaku Kawasaki in 1967 are listed in Table 1 [3, 4]. The disease affects between 12 to 215 per 100,000 children under 5 years of age [5–7]. The median age of the disease at diagnosis is 3.4 years and these patients are most likely to present with classical symptoms [4, 8]. Older children and adolescents between 5 and 18 years represent 23% of cases and frequently present with fewer classic features and are less likely to suffer from meningitis, thrombocytosis, and coronary artery aneurysms [7, 9].

* Correspondence: lgardner1@uq.edu.au
1Department of Clinical Immunology and Allergy, Royal Brisbane and Women’s Hospital, Butterfield Street, Herston, Brisbane, QLD 4029, Australia
2School of Medicine, University of Queensland, Brisbane, Australia
Full list of author information is available at the end of the article

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
diagnostic delay, these patients subsequently have a need to maintain remission. Coupled with the risk of treatment resistance has been identified in older demographics with multiple doses of IVIG re-
function [11]. Treatment resistance has been identified as the duration of inflammation and preventing organ dys-
function [11]. Treatment resistance has been identified in older demographics with multiple doses of IVIG requi-
ded to maintain remission. Coupled with the risk of diagnostic delay, these patients subsequently have a worse prognosis [10].

Case presentation
A previously well 16-year-old female from Central Queens-
land, Australia presented to a regional hospital with a three-
day history of high fevers (39.8 °C) accompanied by myalgia, anorexia and diarrhoea with a single bloody motion on the day of admission. She had not had any sick contacts, recent travel, sexual contact or prior illicit drug use. Her previous history was significant for a hernia repair in 2008, appendec-
tomy in 2011, adenontonsillectomy in 2012, depression, lac-
tose intolerance and autoimmune hypothyroidism. Her immuni-
isations were up-to-date. There were no recent changes to her regular medications with doses of sertraline 25 mg daily and thyroxine 100 micrograms (mcg) during weekdays and 75mcg on weekends. There was a family his-
tory of ulcerative colitis and bronchiectasis.

On examination, at initial presentation, she was febrile and appeared unwell. An erythematous maculopapular rash extended over her abdomen and arms; however, no focal signs of infection were apparent.

Initial investigations
Her laboratory investigations on admission are presented in Table 2.

Clinical Progress
The patient was commenced empirically on cefotaxime 1 g intravenous (IV) 6 hourly and doxycycline 100 mg 12 hourly to cover a potential pulmonary infective source. As noted, she had abnormal liver function tests with a cholestatic predominance. An abdominal ultrasound, performed on Day 4 following symptom onset, demonstrated that her liver measured 15.1 cm in length and had a mildly hyperechoic echotexture. The Gallbladder was reportedly normal with no calculi present. Prominent abdominal lymphadenopathy up to 6 mm was noted.

An infective cause for the fevers was not found despite extensive testing. This included serial blood cultures, serology for Hepatitis A/B/C/E, Cytomegalovirus (CMV), Epstein–Barr virus (EBV), Q Fever, Mycoplasma Pneu-
monia, Leptospirosis, Anti Streptolysin, Rickettsia, Human Immunodeficiency Virus-1 (HIV-1), Mycobacterium tuberculosis (TB), Legionella pneumophila and Dengue.

Autoimmune studies were negative including Antinuclear Antibodies, antibodies to Extractable Nuclear Antigens, anti-tissue transglutaminase (anti-tTG), anti–liver–kidney microsomal antibody-1 (anti-LKM1) and antineutrophil cytoplasmic antibodies (ANCA).

Subsequently, on day 5 following symptom onset, she developed a diffuse swelling of her hands and feet with an associated progression of her rash that resulted in desquamation of her digits. Her tongue took on a straw-
berry red appearance, prominent cervical lymphadenop-
athy developed, her sclera became injected and she became visibly jaundiced.

By day 6 of symptom onset, her serum bilirubin reached its peak of 163umol/L (< 20). The patient then developed an oxygen requirement. Chest x-ray demonstrated mild prominence of pulmonary interstitium suggesting a poten-
tial atypical infection. Despite antibiotics she continued to have recurrent febrile episodes with chest imaging, on Day 7 post symptom onset, demonstrating the development of left lower lobe consolidation.

She was given a provisional diagnosis of Kawasaki disease with the differential including an undetected infective aeti-
ology. Assessment for cardiac involvement demonstrated no ECG changes, Troponin I was initially normal on pres-
entation and an echocardiogram was normal for age.

Treatment
Treatment was commenced on day 8 post symptom on-
set, with Intravenous Immunoglobulin (IVIG) 2 g/kg total in divided doses, low dose Aspirin 150 mg per day and transfer to a tertiary facility for ongoing specialist management. The patient developed acute pulmonary oedema following her last dose of IVIg which responded to intravenous diuretics. Repeat chest x-ray demonstrated bi-basal opacification that was concerning for an

| Table 1 Classical clinical features of kawasaki’s disease [3] |
|-------------------------------------------------------------|
| **A fever lasting 25 days with no other clear cause, combined with four or more of the following:** |
| 1. Oral mucosal changes such as injected / fissured lips, pharyngeal injection or strawberry tongue |
| 2. Bilateral conjunctival injection, without exudate |
| 3. Polymorphous Rash – Maculopapular, Diffuse Erythoderma, Erythema Multiforme-like |
| 4. Peripheral changes including erythema or oedema of the palms/soles (in the acute phase), Periungual desquamation (in the subacute phase) |
| 5. Cervical lymphadenopathy |

They are however more likely to develop hepatitis, cervical lymphadenopathy, and arthralgia [9]. Atypical presenta-
tion and reduced awareness of non paediatric disease mean these patients are more likely to experience diagnos-
tic delay. Consequently 30% of KD patients over the age of 10 years are diagnosed ten days after symptom onset com-
pared to 19% for children under 10 years of age [10].

KD is typically a self-limiting monophasic disease with prognosis linked to diagnostic timing and subsequent expedient administration of intravenous immunoglobu-
lin (IVIG), within 10 days of symptom onset, shortening the duration of inflammation and preventing organ dys-
function [11]. Treatment resistance has been identified in older demographics with multiple doses of IVIG requi-
ded to maintain remission. Coupled with the risk of diagnostic delay, these patients subsequently have a worse prognosis [10].
After 72 h, antibiotics were ceased given marked improvement in chest x-ray finding with diuresis and associated clinical improvement. The patient had a single low-grade fever 2 days after receiving IVIG though continued to improve in all other clinical parameters. She was subsequently discharged on low-dose aspirin with plans for follow up by multiple specialists.

One week following discharge she was experiencing ongoing low-grade fevers (37.6 °C) and left sided pleuritic chest pain. Over the subsequent days, she became progressively unwell with continued low-grade fevers, malaise, lymphadenopathy and a recurrence of conjunctival injection. She received a further 1 g/kg of IVIg over 2 days. Blood tests at this time demonstrated ESR 80 mm/Hr (1–20), CRP 29 mg/L (0–6), total bilirubin 25μmol/L (2–20), normal liver function, normal white cell count though elevated eosinophils 1.53 × 10⁹ (0.04–0.40).

One month later she had made a full clinical and biochemical recovery and aspirin was ceased. Repeat hepatic ultrasound demonstrated resolution of hepatic artery narrowing, a normal appearance of the gall bladder with no intra or extrahepatic bile duct dilation.

**Discussion and conclusions**

This case of an adolescent patient presenting with symptoms consistent with KD illustrates prominent hepatic involvement in comparison to the more usual cardiac involvement.

Phenotypic differences between adult and paediatric KD cases are well described, with older patients more likely to have elevated transaminases, cervical lymphadenopathy and arthralgias, although less likely to develop meningitis, thrombocytosis and coronary artery involvement [12]. Core features of KD present in both groups with similar percentages of fevers, pharyngitis, conjunctivitis and desquamating erythematous rashes [12].

Hepatic involvement is a well-documented complication of KD with 65% of adult onset cases developing hepatitis [12–15]. Patients who develop hepatic failure are typically asymptomatic with resolution of liver dysfunction linked to overall disease activity [13]. The pathogenesis of LFT derangement in KD is incompletely understood but is thought to be multifactorial [13]. This patient’s disease was not monophasic which has previously been described in older patients and particularly those with hepatic involvement [7].

In a subset of cases, patients present with obstructive jaundice and hydrops of the gall bladder. This has been theorised to be due to compressive lymphadenopathy of the porta hepatitis [16]. Less commonly, patients with KD have been found to present with clinical jaundice but without sonographic evidence of hydrops or mechanical obstruction [17–21].

To our knowledge there have been five previous reported cases of obstructive jaundice without evidence of hydrops of the gallbladder which we have summarised in Table 3 [17–21]. In these cases, patients demonstrated normal hepatobiliary anatomy on standard imaging modalities with three reports of nonspecific gallbladder/

---

**Table 2** Initial investigations upon presentation

| Investigation            | Result                          |
|--------------------------|---------------------------------|
| Haemoglobin              | 136 g/L (115–160)               |
| White Cell Count         | 6.1 × 10⁹/L (4–11)              |
| CRP                      | 244 mg/L (< 5)                  |
| ESR                      | 45 mm/Hr (≤ 12)                 |
| ALT                      | 239 U/L (< 45)                  |
| AST                      | 163 U/L (< 35)                  |
| ALP                      | 174 U/L (30–110)                |
| GGT                      | 171 U/L (< 55)                  |
| Total Bilirubin          | 80 μmol/L (≤ 20)                |
| Conjugated Bilirubin     | 58 μmol/L (< 4)                 |
| INR                      | 1.4 (0.9–1.2)                   |
| Albumin                  | 18 g/L (29–42)                  |
| Fibrinogen               | 6 g/L (1.7–4.5)                 |
| Haptoglobin              | 2.7 g/L (0.36–1.95)             |
| Blood Film               | Normal                          |
| Creatinine               | 63 μmol/L (38–82)               |
| Urine - Protein Creatinine Ratio | No Bacterial Growth           |
| Lipase                   | 83 U/L (≤ 60)                   |
| Creatinine Kinase        | 94 U/L (28–142)                 |
| Thyroid Function Tests   | T4 13.0 pmol/L (7–13), TSH 2.9 mU/L (0.3–4.5) |
| BNP                      | 323 ng/L (< 100)                |
| IgG                      | 5.4 g/L (7–16)                  |

---

Inflammatory process. A CT Pulmonary Angiogram demonstrated bi-basal opacification with a differential diagnosis of infection, pulmonary oedema or atelectasis. There was no evidence of a Pulmonary Embolus.

Repeat ultrasound of her liver demonstrated non-specific hepatic artery tapering to 2.5 mm at the porta hepatitis, the Gallbladder had a normal appearance and with no other hepatic or biliary changes. A Renal Artery Duplex ultrasound did not demonstrate renal involvement. Stool polymerase chain reaction (PCR) was negative for viral/bacterial/parasitic aetiology though calprotectin was significantly elevated 2200 μg/g (< 50).

Her Troponin I peaked at 0.051 μg/L (< 0.04) on Day 8 following symptom onset. A CT coronary angiogram (CTCA) was performed which demonstrated no evidence of stenosis, ectasia or aneurysm. Repeat echocardiography demonstrated a mild pericardial effusion but was otherwise normal.

After 72 h, antibiotics were ceased given marked improvement in chest x-ray finding with diuresis and associated clinical improvement. The patient had a single low-grade fever 2 days after receiving IVIG though continued to improve in all other clinical parameters.
biliary dilatation [17–21]. In all cases LFTs returned to normal ranges following administration of IVIG although long term maintenance of normal liver function was not recorded [17–21]. In three cases, a liver biopsy had been performed which demonstrated evidence of intrahepatic cholangitis and bile duct epithelium necrosis without lobular inflammatory infiltrate, or liver cell necrosis that would be found in a viral aetiology. While this histological picture is potentially in keeping with ischemia, no definite vasculitic changes were found, although this may have been due to a lack of sufficiently sized blood vessels in the sample [17]. This suggests that while obstructive jaundice associated with hydrops of the gallbladder may in part be related to localised lymphadenopathy causing physical obstruction, vasculitis involving the liver remains a possibility.

In our case, there was no hydrops of the gallbladder found; however, the non-specific tapering of the hepatic artery seen on ultrasound that resolved with treatment potentially represent vasculitis. The patients identified in the available literature including our patient were older than the median diagnostic age for KD. In infancy an initial broad tolerance prevents reactions against maternal antigens though as the immune system matures autoimmunity becomes more likely [22]. This affects both the innate and adaptive immune system [22]. With increasing expression of toll-like receptors in the innate immune system and increasing selectivity of B and T cell response [22]. Therefore it is speculated that additionally organ systems may be involved in older children and adults as their immune system incorrectly identifies additional antigens [22].

This case was further complicated through the patient’s development of basal consolidation that potentially represented infection, atelectasis, oedema or an inflammatory process. Pulmonary changes responded promptly to the combination of intravenous antibiotics, diuresis and IVIG. Further delineation of the aetiology was not possible however pulmonary involvement of KD is recognised but is rare with a reported incidence on 1.3% [23]. In previous published cases the diagnosis is considered when antimicrobials are not effective leading to diagnostic delay and subsequent association with the development of coronary artery aneurysms [23, 24]. Compared to the previous cases of KD with Cholestatic LFT derangement this is the only case to demonstrate potential pulmonary involvement.

We have reported a rare case of adolescent onset KD presenting with cholestatic jaundice with a relapsing course which required a second administration of intravenous immunoglobulin. Despite this she made a complete clinical recovery receiving appropriate treatment within 10 days following initial diagnostic uncertainty. However, the optimal time period for IVIG administration in this particular population group is unclear. As such it is uncertain if the time in which the patient was undiagnosed contributed to the need for further therapy or whether this population group experiences a longer and less monophasic disease.

| Reference          | Age | Hepatomegaly | Icterus | Abdominal Pain | Serum ALT (x ULN) | Serum AST (x ULN) | Serum ALP (x ULN) | Serum GGT (x ULN) | Serum Bilirubin (umol/L) | Pulmo-nary Involvement | Treatment                                      |
|--------------------|-----|---------------|---------|----------------|-------------------|-------------------|-------------------|-------------------|--------------------------|------------------------|------------------------------------------------|
| Bader-Meurier et al. [17] | 3.5 | +             | +       | NR             | 5                 | 2.5               | 4                 | 15                | 23.9                     | –                      | MG 1 g/kg/day. Not refractory                  |
| Keeling et al. [18] | 12  | +             | +       | +              | 1.91              | 0.80              | 1.43              | 2.63              | 48.9                     | –                      | MG 1.6 g/kg/day. Oral Aspirin. Not refractory  |
| McMahon et al. [19] | 20  | NR            | +       | +              | 4.74              | 2.28              | 1.83              | 4.45              | 134.4                    | –                      | MG 2 g/kg/day. Oral Aspirin. Not refractory.  |
| Valentini et al. [20] | 6   | NR            | +       | +              | 9.96              | 11.87             | 1                 | 10.88             | 121.4                    | –                      | MG 2 g/kg/day. Oral Aspirin. Not refractory.  |
| Vázquez et al. [21] | 6   | +             | +       | NR             | NR                | 3.21              | 4                  | 4.02              | 98.3                     | –                      | MG 2 g/kg/day. Refractory Disease requiring further IVIG 72 h after the 1st dose and 48 h of Methylprednisolone 15-30 mg/kg for 2 days. Oral Aspirin. |

NR Not recorded, ULN Upper Limit of Normal
In summary, hepatic predominant presentations should be considered as an uncommon variant of KD. This presentation appears to be more common in older age groups where treatment resistance is also more common. Subsequently hepatic involvement should suggest the need for closer monitoring in the convalescent phase to exclude recurrence. The mechanism for this presentation is unclear and further research is required. Fortunately, in most cases this is a transient phenomenon, negating the need for invasive investigation.

Abbreviations
ALP: Alkaline phosphatase; ALT: Alanine transaminase; ANCA: Anti-neutrophil cytoplasmic antibodies; anti-LKM1: Anti–liver-kidney microsomal antibody-1; anti-TG: Anti–tissue transglutaminase; AST: Aspartate aminotransferase; ESR: Erythrocyte sedimentation rate; CRP: C reactive Protein; GGT: Gamma-glutamyltransferase; IVIG: Intravenous Immunoglobulin; KD: Kawasaki Disease; LFT: Liver Function Test; NR: Not Recorded; ULN: Upper Limit of Normal

Acknowledgements
Not applicable.

Authors’ contributions
KP and LG reviewed the available literature and synthesised the case. RP, DW, MN, DG read, edited, and approved the final manuscript.

Funding
Funding for publication has been provided by the Department of Clinical Immunology and Allergy at the Royal Brisbane and Women’s Hospital.

Availability of data and materials
Data for this study is stored on Queensland Health pathology database. Access to this data is restricted to Queensland Health employees with a valid clinical reason for access. All data generated or analysed during this study are included in this published article.

Ethics approval and consent to participate
Ethics approval was not required for this study.

Consent for publication
Written and informed consent was gained from the patients’ parents to publish deidentified clinical information and data.

Competing interests
There are no known financial and non-financial competing interests.

Author details
1Department of Clinical Immunology and Allergy, Royal Brisbane and Women’s Hospital, Butterfield Street, Herston, Brisbane, QLD 4029, Australia.
2School of Medicine, University of Queensland, Brisbane, Queensland, Australia.
3Greenslopes Private Hospital, Brisbane, Australia.

Received: 19 March 2020 Accepted: 18 September 2020
Published online: 27 October 2020

References
1. Baker AL, Lu M, Minich LL, Atz AM, Klein GL, Korsin R, et al. Associated symptoms in the ten days before diagnosis of Kawasaki disease. J Pediatr. 2009;154(4):592–5.e2.
2. Bums JC, Mason WH, Glode MP, Shulman ST, Melish ME, Meissner C, et al. Clinical and epidemiologic characteristics of patients referred for evaluation of possible Kawasaki disease. United States multicenter Kawasaki disease study group. J Pediatr. 1991;118(5):680–6.
3. McCrindle BW, Rowley AH, Newburger JW, Bums JC, Bolger AF, Gewitz M, et al. Diagnosis, treatment, and long-term Management of Kawasaki Disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135(17):e927–e99.
4. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Atenugi = [Allergy]. 1967;16(3):178–222.
5. Yamazaki-Nakashimada MA, Espinosa-Lopez M, Hernandez-Bautista V, Espinosa-Padilla S, Espinosa-Rosas F. Catastrophic Kawasaki disease or Juvenile Polyarteritis nodosa? Semin Arthritis Rheum. 2006;35(6):549–54.
6. Holman RC, Belay ED, Christensen KY, Folkema AM, Steiner CA, Schonberger LB. Hospitalizations for Kawasaki syndrome among children in the United States, 1997-2007. Pediatr Infect Dis J. 2010;29(6):483–8.
7. Holman RC, Curns AT, Belay ED, Steiner CA, Schonberger LB. Kawasaki syndrome hospitalizations in the United States, 1997 and 2000. Pediatrics. 2003;112(5):495.
8. Saundankar J, Yim D, Itoh T, Payne R, Maslin K, Jape G, et al. The epidemiology and clinical features of Kawasaki disease in Australia. Pediatrics. 2014;133(4):e1009–14.
9. Wolff AE, Hansen KE, Zakowski L. Acute Kawasaki disease: not just for kids. J Gen Intern Med. 2007;22(5):681–4.
10. Adravini N, Santosso LA, Sastroamoros D. Profile of Kawasaki disease in adolescents: is it different? Acta Med Indones. 2019;51(1):42–6.
11. Durongpisitskul K, Gururaj VJ, Park JM, Martin CF. The prevention of coronary artery aneurysms in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics. 1995;96(6):1057–61.
12. Sepe P, Stankovic K, Small A, Durand DV, Marchand G, Broussole C. Adult Kawasaki disease: report of two cases and literature review. Semin Arthritis Rheum. 2005;34(6):785–92.
13. Badawy M, Domínguez SR, Anderson MS, Glodé MP. Abnormal liver panel in acute Kawasaki disease. Pediatr Infect Dis J. 2011;30(2):141–4.
14. Ting EC, Capparelli EV, Billman GF, Lavine JE, Matsuba T. Elevated gamma-glutamyltransferase concentrations in patients with acute Kawasaki disease. Pediatr Infect Dis J. 1998;17(5):431–2.
15. Uehara R, Yashiro M, Hayasaka S, Ōka I, Nakamura Y, Muta H, et al. Serum alanine aminotransferase concentrations in patients with Kawasaki disease. Pediatr Infect Dis J. 2003;22(9):839–42.
16. Zúñiga F, Falcini F, Zancan L, Martini G, Secchieri S, Luzzatto C, et al. Acute surgical abdomen as presenting manifestation of Kawasaki disease. J Pediatr-Us. 2003;14:6(2):313–5.
17. Badner-Meunier B, Haddouel M, Fabre M, Arnoud MD, Dommergue JP. Intrahepatic bile duct damage in children with Kawasaki disease. J Pediatr. 1992;120(5):750–2.
18. Keeling IM, Beran E, Daupot OE. Kawasaki disease and hepatobiliary involvement: report of two cases. Ital J Pediatr. 2016;42:957.
19. McMahon MA, Wynne B, Murphy GM, Kearns G. Recurrence of Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. J Pediatr-Us. 2003;14:6(2):313–5.
20. Valentini P, Ausili E, Schiavino A, Angelone DF, Focarelli B, De Rosa G, et al. Acute cholestasis: atypical onset of Kawasaki disease. Pediatr Infect Dis J. 2003;22(9):839–42.
21. Vázquez Gomis R, Izquierdo Fos L, López Yañez A, Mendoza Durán M, Serrano Robles MI, Vázquez Gomis C, et al. Cholestatic hepatitis in immunoglobulin-resistant Kawasaki disease; 2016. p. 301–2.
22. Georgeponzouz A, Papadopoulos NG. Postnatal innate immune development: from birth to adulthood. Front Immunol. 2017;8:570.
23. Singh S, Gupta A, Jindal AK, Gupta A, Suri D, Rawat A, et al. Pulmonary presentation of Kawasaki disease-a diagnostic challenge. Pediatr Pulmonol. 2018;53(1):103–7.
24. Arslanoglu Aydin E, Demir S, Aydin O, Bilginer Y, Ozen S. Pleural effusion as an atypical presentation of Kawasaki disease: a case report and review of the literature. J Med Case Reports. 2019;13(1):344.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.